Inhibition of metastatic potential in colorectal carcinoma in vivo and in vitro using immunomodulatory drugs (IMiDs)

BACKGROUND: Thalidomide and lenalidomide are FDA approved for the treatment of multiple myeloma and, along with pomalidomide, are being investigated in various other cancers. Although these agents display immunomodulatory, anti-angiogenic and anti-apoptotic effects, little is known about their prima...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, W M, Henry, J Y, Meyer, B, Bartlett, J B, Dalgleish, A G, Galustian, C
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2009
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2736839/
https://www.ncbi.nlm.nih.gov/pubmed/19638977
http://dx.doi.org/10.1038/sj.bjc.6605206

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2736839/
https://www.ncbi.nlm.nih.gov/pubmed/19638977
http://dx.doi.org/10.1038/sj.bjc.6605206

Ejemplares similares